# A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD)

> **NCT03375255** · PHASE1 · COMPLETED · sponsor: **Sarepta Therapeutics, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Muscular Dystrophy, Duchenne

## Interventions

- **DRUG:** SRP-5051

## Key facts

- **NCT ID:** NCT03375255
- **Lead sponsor:** Sarepta Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-05
- **Primary completion:** 2019-08-19
- **Final completion:** 2019-08-19
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2022-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03375255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03375255, "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03375255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*